US Pre-Market SEC Filings Roundup — May 04, 2026

04-05-2026

Artificial Intelligence Technology Solutions Inc. (AITX) filed an 8-K on May 4, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'AITX to Present at the LD Micro Invitational XVI,' attached as Exhibit 99.1. The information is furnished and not deemed filed or material under securities regulations. No financial or operational metrics were disclosed.

04-05-2026

GMR Solutions Inc., a Delaware-incorporated company in the EMS sector, filed Amendment No. 2 to its Form S-1 registration statement on May 4, 2026, for an initial public offering of 31,914,893 shares of Class A common stock priced between $22.00 and $25.00 per share, with listing on the NYSE under 'GMRS'. Funds affiliated with KKR Stockholder, Ares, and HPS expect to purchase $350,000,000 in private placement warrants concurrently. Post-offering and related transactions, KKR Stockholder will beneficially own approximately 75.5% of voting power, classifying the company as 'controlled' under NYSE rules; no financial performance metrics or declines are detailed in this preliminary prospectus.

• ·Registrant is a non-accelerated filer, not an emerging growth company.
• ·Underwriters have a 30-day option to purchase up to 4,787,233 additional shares for over-allotments.
• ·Principal executive offices: 4400 Hwy 121, Suite 700, Lewisville, TX 75056.
• ·Expected delivery of shares on or about [blank], 2026.

04-05-2026

Willow Lane Acquisition Corp. entered into a Business Combination Agreement on September 15, 2025, with Boost Run Holdings, LLC, Boost Run Inc. (Pubco), and related merger subs for a proposed SPAC business combination. Social media posts regarding the transaction were published by Boost Run, Willow Lane, and Willow Lane CEO B. Luke Weil on April 30, 2026. The filing emphasizes forward-looking statements about potential benefits alongside extensive risks, including deal termination, operational disruptions, and failure to complete the merger.

• ·Commission File No. 001-42400
• ·Filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934

04-05-2026

Odyssey Therapeutics, Inc. filed an S-1/A registration statement for an IPO offering 13,240,000 shares of common stock at a midpoint price of $17.00 per share, expecting approximately $205.2 million in net proceeds (or $236.6 million if underwriters' option for 1,986,000 additional shares is exercised in full), plus $23.3 million from a concurrent private placement of 1,470,588 shares to TPG Orazio II. The company intends to use proceeds to advance OD-001 through phase 2a combination and phase 2b monotherapy trials in ulcerative colitis, SLC15A4 program through IND-enabling and phase 1/2a trials, and other R&D. Financials reflect widening losses with net loss increasing 15% YoY to $148.6 million in 2025 from $129.3 million in 2024, driven by collaboration revenue declining 33% to $3.0 million, R&D expenses rising 12% to $126.6 million, and G&A up 38% to $37.5 million.

• ·1-for-9.7170 reverse stock split of voting common stock effected May 1, 2026
• ·Pro forma net loss per share $5.39 for year ended Dec 31, 2025
• ·4,631,713 shares of common stock issuable upon exercise of options at weighted average $4.94 per share as of Dec 31, 2025
• ·Nasdaq trading symbol proposed as 'ODTX'
• ·No anticipated cash dividends

04-05-2026

Mobia Medical, Inc. filed an S-1/A registration statement (No. 333-295160) on May 4, 2026, as part of its IPO process. The filing highlights a material weakness in internal controls over financial reporting, specifically in the review of inputs for net loss per share attributable to common stockholders, which led to revisions in the statement of operations for the year ended December 31, 2025. The company anticipates substantial increased legal, accounting, and compliance costs as a public company, no plans to pay dividends, and various anti-takeover provisions that could discourage changes in control.

• ·Material weakness remediation involves establishing controls over weighted-average shares outstanding and net loss per share calculation; not yet remediated.
• ·Subject to Section 404 of Sarbanes-Oxley Act requirements post-IPO, including formal assessment of internal controls starting with second annual 10-K.
• ·Anti-takeover provisions include classified board, blank check preferred stock, no stockholder action by written consent, and Section 203 of DGCL.
• ·No intention to pay cash dividends; returns limited to stock appreciation.
• ·Exclusive forum provisions designate Delaware Court of Chancery and U.S. federal courts for certain stockholder disputes.

04-05-2026

Loews Corporation reported Q1 2026 net income attributable to Loews of $337 million ($1.63 per share), down 9% YoY from $370 million ($1.74 per share), driven by a 23% decline in CNA Financial's net income to $194 million due to lower underwriting results, higher loss ratios, and unfavorable reserve development, while Corporate losses widened to $42 million. However, Boardwalk Pipelines' net income rose 5% to $159 million on higher rates and utilization, and Loews Hotels' net income swung to $26 million from near zero, boosted by joint venture equity income. Book value per share increased slightly QoQ to $90.90 from $90.71.

• ·CNA Property & Casualty combined ratio increased to 102.2% from 98.4% YoY; underlying combined ratio to 94.5% from 92.1%.
• ·Parent company had $4.5 billion cash and investments and $1.8 billion debt as of Mar 31 2026.
• ·Total revenues increased to $4,555 million from $4,494 million YoY.
• ·Book value per share excluding AOCI increased to $97.20 from $95.89 QoQ.

04-05-2026

Spectrum Brands Holdings, Inc. entered into a definitive agreement on May 1, 2026, for a $127 million strategic investment from Oaktree Capital Management L.P. in its Home and Personal Care (HPC) business, comprising $67 million in convertible preferred equity and $60 million in a first lien term loan recourse only to HPC. Post-closing, expected on or about May 11, 2026, Oaktree will hold approximately 27% equity stake in HPC, establishing a strategic partnership for long-term growth while removing HPC from the Parent's indebtedness collateral package. No negative financial impacts or declines are disclosed in the filing.

• ·HPC Term Loan is recourse only to the HPC business
• ·Neither party has obligation to make capital contributions into HPC
• ·Transaction expected to close on or about May 11, 2026, subject to regulatory approvals

04-05-2026

Lisata Therapeutics, Inc. entered into an Amendment and Waiver to its March 6, 2026 Merger Agreement with Kuva Labs Inc. (Parent) and Kuva Acquisition Corp. (Purchaser), extending the tender offer commencement deadline from 26 to 59 business days due to Parent's delay, which highlights execution risks in the acquisition process. Parent will make non-refundable Interim Operating Payments totaling $1.1 million to cover Lisata's expenses during the delay, while Lisata waives related claims upon payment and offer commencement. The waiver period runs until May 29, 2026, with cooperation required to avoid further delays.

• ·Waiver Period: From May 3, 2026, until May 29, 2026
• ·Offer commencement extended to 59 Business Days after March 6, 2026
• ·Lisata may terminate waiver sections if Parent misses payments or commits material breach uncured within 2 Business Days
• ·Interim payments terminate upon Offer commencement or Merger Agreement termination

04-05-2026

Cerebras Systems Inc., an AI infrastructure company, filed Amendment No. 1 to its S-1 registration statement on May 4, 2026, for an initial public offering of 28,000,000 shares of Class A common stock at an anticipated price range of $115.00 to $125.00 per share, with listing on Nasdaq Global Select Market under symbol 'CBRS'. The offering includes an underwriters' over-allotment option for up to 4,200,000 additional shares, and post-IPO, outstanding Class B common stock will represent approximately 99.2% of voting power based on beneficial ownership as of March 31, 2026. The prospectus highlights the company's Wafer-Scale Engine 3 (WSE-3) with 4 trillion transistors, 900,000 cores, and claims of superiority over NVIDIA's B200 in scale and performance metrics.

• ·Company incorporated in Delaware, SIC code 3674, EIN 81-2256092.
• ·Principal executive offices: 1237 E. Arques Avenue, Sunnyvale, California 94085.
• ·Emerging growth company electing not to use extended transition period for new accounting standards.
• ·Legal counsel: Latham & Watkins LLP (Tad J. Freese, Sarah B. Axtell, Zuzanna V. Gruca); Davis Polk & Wardwell LLP (Alan F. Denenberg, Elizabeth W. LeBow).

04-05-2026

Crystal Rock Capital Management filed its 13F-HR on May 4, 2026, disclosing 32 equity holdings valued at $168,441,756 as of March 31, 2026, all with sole voting and dispositive power. Top positions include Alphabet Inc Class A ($18,396,651), Vertiv Holdings Co ($16,268,907), Meta Platforms Inc Class A ($16,377,793), and Amazon.com Inc ($10,086,516). The portfolio features concentrated exposure to technology and healthcare names such as NVIDIA, CrowdStrike, Eli Lilly, and Intuitive Surgical.

• ·Filer CIK: 0001510668
• ·SEC File Number: 028-14105
• ·Business address: 2201 Waukegan Road, Suite 245, Bannockburn, IL 60015
• ·Phone: 847-282-7010
• ·All holdings reported with 0 shared power, 0 put/call options

04-05-2026

Bank Hapoalim BM filed its 13F-HR on May 4, 2026, for the period ended March 31, 2026, disclosing total equity and fixed income holdings valued at $651,868,000 across 117 positions. The portfolio is heavily weighted toward ETFs, with top holdings including Vanguard Index Fds S&P 500 ETF SHS at $87,307,000 (146,108 shares sole), Vanguard Bd Index Fds Intermed Term at $39,564,000 (514,490 shares sole), and State Str Spdr S&P 500 ETF T Tr Unit at $35,510,000 (54,602 shares defined). Individual stock positions include major tech names like Microsoft Corp ($10,796,000, 29,165 shares) and Apple Inc ($6,223,000, 24,520 shares), alongside sector ETFs and some principal debt positions.

• ·Signed by Adi Dauber on May 1, 2026.
• ·Notable fixed income: Rivian Automotive Inc Note principal 100000 ($100,000), Solaredge Technologies Inc Note principal 770000 ($770,000), SPDR Series Trust PRN 522551 ($522,551).
• ·Tech-heavy stocks include Nvidia Corporation (17,200 shares, $3,000,000), Amazon Com Inc (89,180 shares, $18,574,000), Alphabet Inc Cap Stk Cl C (60,345 shares, $17,311,000).

04-05-2026

Liftoff Mobile, Inc. filed Amendment No. 1 to its S-1 registration statement on May 4, 2026, for an initial public offering of common stock on Nasdaq under the symbol LFTO, with shares offered at an expected price between $ and $ per share and underwritten by Goldman Sachs, Jefferies, and Morgan Stanley among others. Demand Side Customers grew 21% YoY from 728 in 2024 to 881 in 2025 but slightly declined to 878 in the three months ended March 31, 2026, while apps integrated with its SDK increased 29% YoY to 163,708 and further to 167,814. The platform connects to over 1.4 billion daily active users worldwide in Q1 2026, with pre-IPO majority control by Blackstone affiliates.

• ·Emerging growth company status elected, with non-accelerated filer.
• ·Pre-IPO majority voting control by Blackstone affiliates; potential 'controlled company' post-IPO.
• ·Principal executive offices: 900 Middlefield Road, Redwood City, California 94063.
• ·Intends -for-1 forward stock split prior to offering closing.

04-05-2026

Cabaletta Bio, Inc. plans to present new clinical and translational data from 4 refractory patients treated with rese-cel at the lowest dose without preconditioning in the RESET-PV trial at the ASGCT 2026 Annual Meeting on May 14, 2026, showing clear biologic and clinical activity after discontinuing immunomodulators, with 2 of 4 patients demonstrating compelling activity through 6 months, 3 of 4 off all immunomodulators and steroids, and complete peripheral B cell elimination in 3 of 4. Safety was favorable with Grade 1 CRS in 1 of 4 patients and no ICANS observed. Multiple additional patients have been enrolled at a higher dose in RESET-PV with durability data expected in H2 2026, while the initial dose cohort in the RESET-SLE trial is fully enrolled with data anticipated in H1 2026.

• ·Data cut-off date: April 2, 2026
• ·Presentation date: May 14, 2026 at ASGCT 2026 Annual Meeting
• ·RESET-PV is first study in RESET program without cyclophosphamide and fludarabine preconditioning
• ·Higher dose cohort in RESET-PV: multiple additional patients enrolled; durability data anticipated H2 2026
• ·RESET-SLE initial dose cohort fully enrolled; initial data anticipated H1 2026

04-05-2026

TG-17, Inc. (OBAI), through its CEO Doron Kempel, filed Amendment No. 1 to the Certificate of Designations, Preferences and Rights of its Series C Convertible Preferred Stock, originally filed on September 16, 2025. The amendment, approved by the Board of Directors and requisite shareholders on May 4, 2026, adds a new Section 4(f) imposing a leak-out restriction: holders collectively cannot sell more than 10% of daily trading volume in conversion shares, unless sold at or above 115% of the prior day's closing sale price. All other provisions remain unchanged.

• ·Amendment executed pursuant to Nevada Revised Statutes Section 78.1955
• ·Original Certificate of Designations filed September 16, 2025

04-05-2026

National Vision Holdings, Inc. (EYE) filed a DEFA14A Definitive Additional Materials proxy statement on May 04, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as filed by the registrant. No financial metrics, performance data, or substantive proxy details are provided in the document header.

• ·Filing Type: DEFA14A (Definitive Additional Materials)
• ·Filed by the Registrant
• ·No fee required

04-05-2026

Berkshire Hathaway's Q1 2026 total revenues increased 4.4% YoY to $93,675 million from $89,725 million, with sales and service revenues up 6.6% to $50,946 million, while insurance premiums grew modestly 0.9% to $22,005 million. Net earnings attributable to Berkshire shareholders more than doubled to $10,106 million from $4,603 million (+119.5%), boosted by smaller investment losses of $(1,605) million versus $(6,435) million and higher pre-tax operating earnings. However, equity securities decreased to $288,034 million from $297,778 million (-3.4%), operating cash flows fell slightly 4.3% to $10,438 million from $10,903 million, and interest/dividend income declined to $5,430 million from $5,632 million.

• ·Acquisitions of businesses used $9,690 million cash in Q1 2026.
• ·Purchases of equity securities $15,938 million and sales $24,087 million in Q1 2026.
• ·Treasury stock acquisitions $235 million in Q1 2026.
• ·Short-term investments in U.S. Treasury Bills increased to $339,261 million from $321,434 million.
• ·Net cash flows from investing activities improved to $(4,308) million from $(16,401) million YoY.

04-05-2026

Blueport Acquisition Ltd (Nasdaq: BPAC), a SPAC, and SingAuto Inc announced a definitive business combination agreement valued at $1.2 billion, under which SingAuto shareholders will receive approximately 120,000,000 ordinary shares of the resulting PubCo at $10.00 per share. The transaction involves a reincorporation merger followed by an acquisition merger, with closing expected by end of 2026 subject to regulatory approvals, shareholder votes, SEC review of the proxy/prospectus, and Nasdaq listing. No financial performance metrics or declines are disclosed, though forward-looking statements highlight execution risks including potential failure to close or realize benefits.

• ·SingAuto headquartered in Singapore, operates in Singapore and Middle East, focuses on CEVs for cold-chain logistics including frozen, chilled, fresh produce, and pharmaceuticals.
• ·Transaction unanimously approved by boards of both companies.
• ·Advisors: Loeb & Loeb LLP and Ogier (Blueport); Robinson & Cole LLP, ShookLin & Bok, Ogier (SingAuto).
• ·Form F-4 registration statement to be filed including proxy statement/prospectus.
• ·Filing references Blueport's Form 10-K for FY ended December 31, 2025, filed February 26, 2026.

04-05-2026

At a special shareholder meeting on May 1, 2026, Farmer Bros. Co. stockholders approved the Merger Agreement with Royal Cup, Inc., with 13,931,965 votes in favor, 1,922,713 against, and 174,645 abstentions (86.9% approval on votes cast). The non-binding advisory vote on merger-related executive compensation also passed with 10,568,703 votes for (65.9%) but faced notable opposition of 4,098,960 votes against and 1,361,660 abstentions. The adjournment proposal received 13,698,466 votes in favor (85.5%) but was not needed as the merger was approved.

• ·Record date for Special Meeting: March 19, 2026.
• ·Proxy statement filed with SEC on March 27, 2026, supplemented on April 21, 2026 and April 24, 2026.
• ·No broker non-votes for any proposal.
• ·Adjournment not pursued as Merger Proposal approved.

04-05-2026

Community West Bancshares announced that its Executive Management will meet with investors at the D.A. Davidson Financial Institutions Conference in Nashville, Tennessee, on May 4-6, 2026. A copy of the investor presentation (Exhibit 99.1) is furnished with this 8-K filing under Item 7.01.

• ·Filing dated May 1, 2026 (earliest event reported)
• ·Securities: Common Stock, no par value (CWBC on NASDAQ)

04-05-2026

Archrock, Inc. held its 2026 Annual Meeting of Stockholders on April 30, 2026, where stockholders elected nine directors with votes for ranging from 135,412,040 to 148,506,194 shares and withheld votes from 467,599 to 13,561,753, alongside consistent broker non-votes of 9,604,372. Proposal 2 to ratify Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026, passed with 151,795,016 votes for versus 6,678,242 against and 104,907 abstentions. Proposal 3, an advisory vote approving 2025 Named Executive Officer compensation, passed with 146,383,133 votes for versus 2,398,197 against and 192,463 abstentions.

• ·Proxy statement filed with SEC on March 17, 2026
• ·Form 8-K filed on May 04, 2026; signed May 01, 2026

04-05-2026

AI Financial Corporation (formerly ALT5 Sigma Corporation, NASDAQ: ALTS) began trading under its new Nasdaq ticker symbol AIFC effective April 29, 2026, following cessation of trading under ALTS on April 28, 2026, to reflect its evolution toward a platform supporting payments, tokenization, and AI-driven infrastructure. The company has processed more than $8 billion in cumulative transaction volume since inception, serving institutional and enterprise clients. No action is required by stockholders, with uninterrupted Nasdaq trading and unchanged CUSIP and Frankfurt ticker (5AR1).

• ·Filing Date: May 04, 2026; Items: 5.03, 7.01, 9.01
• ·Investor Relations: Gateway Group, Inc., Phone: +1 (949) 574-3860, Email: AIFC@gateway-grp.com

04-05-2026

Collective Acquisition Corp. II priced its initial public offering at $220,000,000, consisting of 22,000,000 units at $10.00 per unit, with units to list on Nasdaq under 'CAIIU' starting April 29, 2026, and closing expected on April 30, 2026. Each unit includes one Class A ordinary share and one-half redeemable warrant exercisable at $11.50 per share. The blank check company, led by CEO Daniel Hoffman and Chairman Samuel Sayegh, focuses on mergers in sectors like defense technology and AI, with underwriters granted an option for 3,300,000 additional units.

• ·Units expected to separate for individual trading as 'CAII' (shares) and 'CAIIW' (warrants)
• ·Underwriter: Clear Street LLC (sole book-running manager)
• ·Legal counsel: Reed Smith LLP (Company), Walkers (Cayman) LLP (Cayman counsel), Morgan, Lewis & Bockius LLP (underwriters)
• ·Registration statement effective April 28, 2026
• ·45-day over-allotment option

04-05-2026

SpringBig Holdings, Inc. filed a 10-K/A amendment on May 04, 2026, solely to provide Part III information including equity compensation plans and beneficial ownership as of December 31, 2025. Equity compensation plans approved by stockholders show 7,442,566 securities to be issued upon exercise at a weighted-average price of $0, with no securities remaining available for further issuance. Beneficial ownership reveals high concentration among 5% stockholders: Mark Silver (19,899,999 shares, 29.1%), Lightbank Asset Management, LLC (16,000,000 shares, 24.8%), and others, while executives and directors as a group hold only 797,133 shares (1.6%).

• ·Equity compensation plans have weighted-average exercise price of $0.
• ·No securities remaining available for further issuance under equity compensation plans (in thousands).
• ·Jaret Christopher granted 12,891,251 restricted shares on April 1, 2026, with 8,320,939 vesting immediately.
• ·Company is a small business, emerging growth company, non-accelerated filer with entity public float of $1.4M.

04-05-2026

OneMeta Inc. reported revenue of $1,505,866 for the year ended December 31, 2025, a 4710% YoY increase from $31,304 in 2024, fueled by new partnerships including OEM agreements with inContact (NICE Ltd. affiliate), Genesys AppFoundry, and Five9 ISV program. However, the company posted a net loss of $3,839,617, improved from $4,595,555 in 2024 but still reflecting high operating expenses with R&D up 36% YoY to $1,178,595 and total operating expenses rising 6% to $4,779,764. The filing also discloses $2,765,000 in new convertible notes and 1.1 million common shares issued in unregistered sales during 2025.

• ·Verbum priced at $0.30-$0.36 per minute vs. human interpreters $1.25-$3.00 per minute.
• ·Unregistered securities issued to entities including Invictus General Partners (1M shares at $0.50), Jarman Family Holdings LLC ($1M note), Jeffrey M. Canter ($1M note).
• ·Partnership agreements dated: Oct 8, 2024 (inContact), Aug 22, 2024 (Genesys), Jul 22, 2024 (Five9).

04-05-2026

Flora Growth Corp. reported Q1 2026 revenue of $7,274 up 6% YoY from $6,866, with gross profit surging to $3,146 from $535 due to lower cost of sales. However, a $60,742 loss from changes in fair value of digital assets drove operating expenses to $65,799 and a $36,660 net loss from continuing operations, compared to $341 prior year, while total assets fell 65% QoQ to $45,190 from $130,235 and cash dropped to $1,978 from $5,596. Shareholders' equity declined to $36,797 from $70,552 amid significant share dilution to 2,430 outstanding from 1,046.

• ·Net cash used in operating activities $3,847 in Q1 2026 vs $2,661 prior year.
• ·No loss from discontinued operations in Q1 2026 vs $417 loss prior year.
• ·Long-term debt reduced to $38 from $50,767 QoQ.
• ·Restricted digital assets $0 vs $49,000 QoQ.

04-05-2026

Immersion Corp reported total revenues of $518,488 thousand for the three months ended January 31, 2026, up 9.9% YoY to $518.5M, driven by Barnes & Noble Education's product and other sales growth of 12.4% to $471,825 thousand; however, Immersion's core royalty and license revenue declined 59.7% to $3,396 thousand, rental income was flat at +0.2%, and the company posted a net loss attributable to stockholders of $10,266 thousand versus $24,061 thousand profit last year. For the nine months ended January 31, 2026, revenues increased 14.9% YoY to $1,460,694 thousand with BNED strength, but Immersion royalties plunged 81.7% to $13,028 thousand, resulting in net income attributable to stockholders of just $795 thousand compared to $81,942 thousand prior year. Total assets expanded 29.9% to $1,432,720 thousand as of January 31, 2026 from $1,102,273 thousand at April 30, 2025, reflecting BNED consolidation.

• ·Previously-issued financial statements restated (Note 3)
• ·Business combination discussed (Note 4)
• ·Noncontrolling interest in consolidated subsidiaries: $266,619 thousand as of Jan 31, 2026
• ·Dividends declared: $2,516 thousand in Q3 FY2026
• ·Stock repurchases: 1,700 shares for $10 thousand in Q3 FY2026
• ·Impairment loss: $1,018 thousand in Q3 FY2026
• ·Filing includes disclosures on restatement, business combination, participation interest purchase agreement (Note 11), and subsequent events (Note 20)

04-05-2026

For the three months ended March 31, 2026, total operating revenue increased 4.8% YoY to $6,672 million, with energy revenue up 5.5% to $5,810 million while real estate revenue was essentially flat at $862 million. Operating income rose 5.4% YoY to $1,458 million; however, net income attributable to BHE shareholders declined 6.2% to $1,114 million due to higher interest expense and reduced other income. Total assets expanded 2.5% QoQ to $152,029 million as of March 31, 2026, supported by cash surging 148% to $4,203 million, though property, plant and equipment net decreased 0.7% to $111,566 million.

• ·Wildfires liabilities (current portion) decreased QoQ to $160M from $734M.
• ·Short-term debt decreased QoQ to $1,005M from $1,997M.
• ·Interest expense increased 8.7% YoY to $746M.
• ·Subsidiary senior debt increased to $45,500M from $42,759M as of December 31, 2025.

04-05-2026

Illumina reported Q1 2026 total revenue of $1,091M, up 4.8% YoY from $1,041M, driven by 4.2% growth in product revenue to $917M and 8.1% in services to $174M, while gross profit rose 5.6% to $721M and operating income surged 27.4% to $209M due to modestly lower operating expenses. However, other expense net swung to a $52M loss from $18M income, causing pre-tax income to decline 13.7% to $157M, with net income up slightly 2.3% to $134M; cash and equivalents fell $329M QoQ to $1,089M amid $415M paid for acquisitions and $242M share repurchases.

• ·Acquired net assets include $171M goodwill and $186M intangible assets.
• ·Net cash provided by operating activities increased 20.4% YoY to $289M.
• ·Term debt steady at $1,990M total (current $499M + long-term $1,490M).

04-05-2026

Aura Biosciences appointed Natalie Holles as Chief Executive Officer, President, and Board member effective April 30, 2026, succeeding founder Elisabet de los Pinos, Ph.D., who stepped down from her roles. The Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) in early choroidal melanoma has enrolled 86 patients as of May 4, 2026, with over 25 additional patients scheduled or identified for screening through May 2026, on track for enrollment completion by mid-2026 and topline data in the second half of 2027. No declines or flat performance metrics were reported.

• ·CoMpass trial is under Special Protocol Assessment agreement with FDA and has Orphan Drug Designation from FDA and EMA, plus Fast Track designation from FDA.
• ·Natalie Holles has over 25 years of experience, including prior CEO roles at Third Harmonic Bio and Audentes Therapeutics.

04-05-2026

On May 3, 2026, Modiv Industrial, Inc. and its Operating Partnership entered into a Merger Agreement with Global Net Lease, Inc. and affiliates, providing for Modiv to merge into a GNL subsidiary, with holders of Modiv Class C common stock receiving 1.975 shares of GNL common stock per share and holders of 7.375% Series A Preferred Stock receiving $25.00 per share in cash plus accrued dividends. The transaction, approved by both boards, requires Modiv shareholder approval, NYSE listing of GNL shares, tax opinions, and absence of material adverse effects, with an outside date of February 3, 2027. Termination fees of $10M or $15M apply in specified scenarios, including superior proposals or breaches.

• ·Modiv Class C common stock and preferred stock to be delisted from NYSE and deregistered under Exchange Act post-merger.
• ·Class X Units in Operating Partnership to vest into Class C Units immediately prior to OpCo Merger, then convert to 1.975 GNL OP Units.
• ·Company must convene special stockholder meeting for majority approval of Company Merger.
• ·GNL to file Form S-4 Registration Statement including proxy statement with Company Board recommendation to vote in favor.

04-05-2026

On May 3, 2026, Global Net Lease, Inc. (GNL) entered into a definitive Merger Agreement with Modiv Industrial, Inc. and its operating partnership, under which Modiv will merge into GNL's merger sub, with Modiv common stockholders receiving 1.975 shares of GNL common stock per share and Modiv preferred stockholders receiving $25.00 in cash plus accrued dividends per share. The transaction also involves an OP merger with equivalent 1.975 exchange ratio for OP units, subject to stockholder approval, NYSE listing, tax opinions, and other customary closing conditions, with an outside date of February 3, 2027. Termination fees of $10,000,000 or $15,000,000 may apply under specified circumstances.

• ·Unanimous board approvals from both GNL and Modiv.
• ·Modiv stockholder meeting required for majority approval of the merger.
• ·GNL to file Form S-4 Registration Statement including Proxy Statement/Prospectus.
• ·Tax opinions required confirming REIT status and Section 368(a) reorganization treatment.
• ·Transition services agreements with Aaron Halfacre and John Raney post-closing.
• ·GNL OpCo Partnership Agreement Amendment to include OP Unit Call Right.

04-05-2026

Yahav Achim Ve Achayot - Provident Funds Management Co Ltd., a Tel Aviv-based firm, filed Form 13F-HR on May 04, 2026, disclosing 26 equity holdings as of March 31, 2026, with no changes reported during the quarter. Top holdings by market value include Invesco QQQ Trust (11,642 shares valued at $6,719,530), VanEck Semiconductor ETF (13,203 shares at $5,062,030), Tower Semiconductor Ltd (27,858 shares at $4,888,522), Global X US Infrastructure Development ETF (62,840 shares at $3,192,900), and BWX Technologies Inc (15,205 shares at $3,109,270). The portfolio is heavily weighted toward technology, semiconductors, ETFs, and select industrials.

• ·Report period end date: March 31, 2026
• ·Filing date: May 04, 2026
• ·No additions or reductions reported (all positions show 0 0 for changes)
• ·Business address: 14 Weitzman St., Tel-Aviv L3 6423914
• ·Phone: 9723541394
• ·SEC file number: 028-21424

04-05-2026

Apimeds Pharmaceuticals US, Inc. entered into a Settlement Agreement on April 24, 2026, resolving disputes from a prior Merger Agreement, under which Lokahi Therapeutics retains the Apitox program and provides a $4M working capital contribution plus forgiveness of a $750k advance, while the Company forms Newco and distributes 51% of Lokahi stock. Concurrently, a Forbearance Agreement with Alto Opportunity Master Fund grants temporary relief from defaults on an $11M convertible note until June 30, 2026, subject to strict conditions including timely 10-K filing and NYSE compliance. However, the Side Letter allows potential merger unwind if the 10-K is delayed past April 30, 2026 or receives a qualified audit opinion, and board changes introduce interim uncertainty with Mr. Koo's resignation and planned transition to new directors.

• ·Irrevocable proxy granted by Inscobee Parties to Dr. Vin Menon and Captain Sandeep Singh Yadav until the later of NYSE approval, Preferred Stock Conversion, NYSE denial, or July 30, 2026.
• ·Newco to receive 10% of net financing proceeds from Company's existing investor arrangement; spin-off expected within 12 months, extendable by another 12 months.
• ·Forbearance Conditions include 10-K filing by April 30, 2026, registration statement effective by June 30, 2026, 1-for-10 reverse stock split, and NYSE compliance by June 30, 2026.
• ·Stockholder Consents purporting to remove directors declared void; board temporarily reduces to three members during Interim Period until 10-K filing.

04-05-2026

George Furlan resigned as Director and Interim Chief Executive Officer effective April 24, 2026, with the resignation accepted by the Board on May 1, 2026, and no disagreements on company operations, policies, or practices. The Board, now consisting of Eric Bruns (Chairman) and Dionne Harvey Pendleton, designated Serge Knazev (President and COO since January 1, 2026) as Acting Principal Executive Officer effective May 1, 2026, pending searches for a permanent CEO and new director. Compensation owed to Mr. Furlan for periods ended December 31, 2025, and March 31, 2026, is under review, with no separation agreement entered as of the filing date.

• ·Resignation informed telephonically on April 24, 2026; written notice received April 29, 2026.
• ·Company will amend this 8-K within four business days if material separation terms are determined for Mr. Furlan.

04-05-2026

CNA Financial reported Q1 2026 net income of $211 million ($0.78 per share), down from $274 million ($1.00 per share) in Q1 2025, with core income of $225 million ($0.83 per share) versus $281 million ($1.03 per share). Property & Casualty core income declined to $248 million from $311 million amid a combined ratio of 102.2% (up from 98.4%) and underlying combined ratio of 94.5% (up from 92.1%), though net written premiums grew 1% to $2,622 million and net investment income rose to $610 million. Life & Group swung to a $9 million core loss from $6 million income, while Corporate & Other loss improved to $14 million from $36 million; the board declared a $0.48 quarterly dividend.

• ·Book value per share excluding AOCI of $45.12, up 1% from year-end 2025 adjusted for $2.48 dividends per share.
• ·New business grew 3% to $581 million with retention at 83%.
• ·Excluding currency, International NWP grew 7%.

04-05-2026

Fervo Energy Company filed an S-1/A amendment for its initial public offering of 55,555,555 shares of Class A common stock, priced between $21.00 and $24.00 per share, with plans to list on NASDAQ under the symbol 'FRVO'. Cornerstone Investors have indicated interest in purchasing up to $350 million in shares. Post-IPO, CEO Tim Latimer and CTO Jack Norbeck will beneficially own 2.89% of outstanding capital stock but control 54.37% of voting power via Class B shares.

• ·Underwriters granted 30-day option for additional 8,333,333 shares.
• ·Emerging growth company and smaller reporting company status elected.
• ·Principal executive offices at 811 Main Street, Suite 1700, Houston, TX 77002.

04-05-2026

Imunon, Inc. (IMNN) filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders on June 16, 2026, at 10:00 a.m. ET virtually, with a record date of April 17, 2026, and 3,983,342 shares of common stock outstanding. Shareholders will vote on Proposal 1 (election of Class I directors by plurality), Proposal 2 (ratification of WithumSmith+Brown PC as independent auditors for the year ending December 31, 2026), Proposal 3 (non-binding advisory approval of 2025 Named Executive Officer compensation), and Proposal 4 (amendment to the 2018 Stock Incentive Plan). No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Voting methods: internet at www.proxyvote.com, phone, proxy card, or live webcast at www.virtualshareholdermeeting.com/IMNN2026 using 16-digit control number
• ·Broker non-votes expected only on Proposal 2 (routine); non-routine for Proposals 1, 3, 4
• ·2025 Annual Report on Form 10-K available at www.sec.gov or www.imunon.com

04-05-2026

Sphere 3D Corp. filed Definitive Additional Materials (DEFA14A proxy statement) on May 04, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was submitted by the registrant with no fee required. No substantive proxy details, financial data, or voting matters are included in the provided filing content.

04-05-2026

Cushman & Wakefield U.S. Borrower, LLC, a wholly-owned subsidiary of Cushman & Wakefield Ltd., elected on April 30, 2026, to partially redeem $100 million of its outstanding $650 million 6.750% Senior Secured Notes due May 2028. The redemption is scheduled for May 15, 2026, at 100% of the principal amount plus accrued and unpaid interest up to but excluding the redemption date. This action reduces the outstanding principal by approximately 15.4%, with no other performance metrics reported.

• ·Notification provided to Trustee on April 30, 2026.
• ·Redemption notice to be issued in accordance with the Indenture.
• ·This 8-K does not constitute an official notice of redemption.

04-05-2026

Arbejdsmarkedets Tillaegspension filed its 13F-HR on May 4, 2026, disclosing 169 U.S. equity holdings totaling $4,019,890,212 as of March 31, 2026, all held with sole discretionary voting authority. Top positions include NextEra Energy Inc at $25,685,035 (276,540 shares), Newmont Corp at $27,698,252 (255,873 shares), and National Fuel Gas Co at $25,688,852 (273,402 shares). No changes, additions, or reductions are indicated in this quarterly snapshot filing.

• ·Filer CIK: 0002105395
• ·LEI: 549300Y1IIQ0WYJR9F68
• ·Business address: Kongens Vaenge 8, Hilleroed, G7 3400
• ·SEC file number: 028-26080

04-05-2026

AMF Tjanstepension AB filed its 13F-HR report on May 4, 2026, disclosing $15,083,420,610 in total US equity holdings as of March 31, 2026, across 117 positions, all held with sole investment discretion and sole voting power. Top holdings by value include NVIDIA Corporation at $1,428,831,296 (8,192,840 shares), Microsoft Corporation at $1,046,775,980 (2,827,825 shares), and Apple Inc. at $827,063,795 (3,258,851 shares). The portfolio features significant exposure to technology, financials, and healthcare sectors.

• ·All positions reported with sole voting power (no shared or other voting authority).
• ·No put or call options held.
• ·Former company name: AMF Pensionsforsakring AB (name changed 07/05/2012).

04-05-2026

TRIGLAV INVESTMENTS, D.O.O., a Slovenia-based institutional investment manager formerly known as TRIGLAV SKLADI, D.O.O., filed its 13F-HR on May 4, 2026, disclosing 166 equity positions held as of March 31, 2026, all with sole voting power. Top holdings include NVIDIA CORPORATION ($139635325), AMAZON.COM, INC. ($94875132), MICROSOFT CORPORATION ($89128700), APPLE INC. ($82845921), and ALPHABET INC. ($66042709). The filing provides a snapshot of diversified US-listed equity exposure with no reported changes, additions, or reductions indicated.

• ·Filer address: Dunajska Cesta 20, Ljubljana, Slovenia 1000
• ·Former company name: TRIGLAV SKLADI, D.O.O. (name change date: 20250213)
• ·All positions reported as SH SOLE (sole voting power), no put/call or shared discretion indicated
• ·SEC file number: 028-25151

04-05-2026

Norwegian Cruise Line Holdings reported strong Q1 2026 results with total revenue up 10% YoY to $2.3 billion, Adjusted EBITDA up 18% to $533 million exceeding guidance, and Adjusted EPS doubling to $0.23. However, the company lowered full-year 2026 guidance due to Middle East disruptions, softer demand especially in Europe, and being behind its booking curve, with Net Yield expected down 3.0%-5.0% on a constant currency basis and Adjusted EPS at $1.45-$1.79. SG&A optimization initiatives are projected to yield $125 million in annualized run-rate savings, while Q2 Net Yield is guided to decline 3.6% on a constant currency basis.

• ·Net Leverage ended Q1 2026 at 5.3x.
• ·Fuel expense Q1 2026: $169 million; fuel price per metric ton net of hedges $651 (down from $687 prior year).
• ·FY 2026 Capacity Days guidance: ~26.25 million; Occupancy ~104.2%.
• ·Newbuild-and-Growth Capex FY 2026 net of financing: ~$1.3B.
• ·Hedged 51% of 2026 fuel consumption at blended price $534 per metric ton.

04-05-2026

Norwegian Cruise Line Holdings reported strong Q1 2026 results with total revenue up 10% YoY to $2.3 billion, Adjusted EBITDA up 18% to $533 million exceeding guidance, and Adjusted EPS doubling to $0.23. However, the company lowered full-year 2026 guidance due to Middle East disruptions, softer demand especially in Europe, and being below the optimal booking curve, with Net Yield on a Constant Currency basis now expected down 3-5% and Adjusted EPS at $1.45-$1.79. Additional positives include $125 million in annualized SG&A savings and delivery of Norwegian Luna, but Net Yield declined 0.3% YoY in Q1.

• ·Net Leverage at 5.3x as of March 31, 2026.
• ·Fuel price per metric ton net of hedges $651 in Q1 2026 vs $687 in Q1 2025.
• ·51% of 2026 fuel consumption hedged at blended price $534 per metric ton.
• ·FY2026 newbuild-and-growth capex gross ~$2.9B, net of financing ~$1.3B.
• ·Q2 2026 Adjusted EBITDA guidance ~$632M.